

HSCT GVHD Endpoints by Quarter: 2025 Transplant Cohort

Quarterly Analysis of Acute and Chronic GVHD

Transplant Outcomes Analysis

2026-01-21

Note

This report was generated using AI under general human direction. At the time of generation, the contents have not been comprehensively reviewed by a human analyst.

Executive Summary

This report analyzes GVHD endpoints for **26 patients** who underwent HSCT during calendar year 2025, broken down by quarter (trimester).

GVHD Endpoints Analyzed:

1. **Acute GVHD Grade II-IV:** Clinically significant acute GVHD
2. **Chronic GVHD (Total):** Any chronic GVHD
3. **Chronic GVHD (Mild):** Mild chronic GVHD
4. **Chronic GVHD (Moderate-Severe):** Moderate or severe chronic GVHD

Quarterly Distribution:

- ****Q1 2025**:** 7 transplants
- ****Q2 2025**:** 4 transplants
- ****Q3 2025**:** 8 transplants
- ****Q4 2025**:** 7 transplants

Overall GVHD Results:

- **Acute GVHD Grade II-IV:** 7 (26.9%)

- **Chronic GVHD (Any):** NA (NA%)
- **Chronic GVHD (Mild):** 1 (3.8%)
- **Chronic GVHD (Moderate-Severe):** 4 (15.4%)

 Limited Follow-up Period

This cohort has **limited follow-up time** with transplants occurring throughout 2025. Chronic GVHD typically manifests 3-12+ months post-transplant, so rates may be underestimated, particularly for Q3 and Q4 2025 patients.

Methodology

Endpoint Definitions

****Acute GVHD Grade II-IV:****

- Clinically significant acute GVHD
- Includes Grade II, III, and IV
- Excludes Grade I (mild) and no acute GVHD

****Chronic GVHD (Total/Any):****

- Any chronic GVHD regardless of severity
- Includes Mild, Moderate, and Severe

****Chronic GVHD (Mild):****

- Limited/mild chronic GVHD only

****Chronic GVHD (Moderate-Severe):****

- Moderate or severe chronic GVHD

- Clinically significant chronic GVHD requiring treatment

****Current Cohort Events:****

- Acute GVHD Grade II-IV: 7 event(s)
- Chronic GVHD (Any): NA event(s)
- Chronic GVHD (Mild): 1 event(s)
- Chronic GVHD (Moderate-Severe): 4 event(s)

Calculation Methods

All GVHD rates calculated as simple percentages:

- **GVHD Rate (%) = (Number of Events / Total N) × 100**
 - Results shown as: “events/total (percentage%)”
-

Acute GVHD Grade II-IV Analysis

Acute GVHD II-IV by Quarter - Overall

Table 1: Acute GVHD Grade II-IV by Quarter

Quarter	N	Events	Acute GVHD II-IV Rate (n/N %)
Q1 2025	7	2	2/7 (28.6%)
Q2 2025	4	0	0/4 (0%)
Q3 2025	8	4	4/8 (50%)
Q4 2025	7	1	1/7 (14.3%)

Acute GVHD II-IV by Quarter and Complete Remission Status

Table 2: Acute GVHD Grade II-IV by Quarter and Complete Remission Status

Quarter	Disease Status	N	Events	Acute GVHD II-IV Rate (n/N %)
Q1 2025	Complete Remission	5	2	2/5 (40%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)
Q2 2025	Not in Complete Remission	2	0	0/2 (0%)
Q3 2025	Complete Remission	8	4	4/8 (50%)
Q4 2025	Complete Remission	5	1	1/5 (20%)
Q4 2025	Not in Complete Remission	2	0	0/2 (0%)

Acute GVHD II-IV by Quarter and Donor Type

Table 3: Acute GVHD Grade II-IV by Quarter and Donor Type

Quarter	Donor Type	N	Events	Acute GVHD II-IV Rate (n/N %)
Q1 2025	MUD	4	0	0/4 (0%)
Q1 2025	MMUD	2	1	1/2 (50%)
Q1 2025	Haploidentical	1	1	1/1 (100%)
Q2 2025	MUD	1	0	0/1 (0%)
Q2 2025	Sibling HLA-identical	2	0	0/2 (0%)
Q2 2025	Haploidentical	1	0	0/1 (0%)
Q3 2025	Haploidentical	3	3	3/3 (100%)
Q3 2025	MMUD	3	0	0/3 (0%)
Q3 2025	MUD	2	1	1/2 (50%)
Q4 2025	Haploidentical	3	1	1/3 (33.3%)
Q4 2025	MMUD	2	0	0/2 (0%)
Q4 2025	MUD	2	0	0/2 (0%)

Acute GVHD II-IV by Quarter, Donor Type, and CR Status

Table 4: Acute GVHD Grade II-IV by Quarter, Donor Type, and Complete Remission Status

Quarter	CR Status	Donor Type	N	Events	Acute GVHD II-IV Rate (n/N %)
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)
Q1 2025	Complete Remission	MMUD	1	1	1/1 (100%)
Q1 2025	Complete Remission	Haploidentical	1	1	1/1 (100%)

Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	0	0/2 (0%)
Q3 2025	Complete Remission	Haploidentical	3	3	3/3 (100%)
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)
Q3 2025	Complete Remission	MUD	2	1	1/2 (50%)
Q4 2025	Complete Remission	Haploidentical	3	1	1/3 (33.3%)
Q4 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q4 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)

Chronic GVHD Analysis

Chronic GVHD (Total/Any) by Quarter - Overall

Table 5: Chronic GVHD (Any) by Quarter

Quarter	N	Events	Chronic GVHD (Any) Rate (n/N %)
Q1 2025	7	1	1/7 (14.3%)
Q2 2025	4	1	1/4 (25%)
Q3 2025	8	3	3/8 (37.5%)
Q4 2025	7	NA	NA/7 (NA%)

Chronic GVHD (Total/Any) by Quarter and Complete Remission Status

Table 6: Chronic GVHD (Any) by Quarter and Complete Remission Status

Quarter	Disease Status	N	Events	Chronic GVHD (Any) Rate (n/N %)
Q1 2025	Complete Remission	5	1	1/5 (20%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)
Q2 2025	Not in Complete Remission	2	1	1/2 (50%)

Q3 2025	Complete Remission	8	3	3/8 (37.5%)
Q4 2025	Complete Remission	5	NA	NA/5 (NA%)
Q4 2025	Not in Complete Remission	2	NA	NA/2 (NA%)

Chronic GVHD (Total/Any) by Quarter and Donor Type

Table 7: Chronic GVHD (Any) by Quarter and Donor Type

Quarter	Donor Type	N	Events	Chronic GVHD (Any) Rate (n/N %)
Q1 2025	MUD	4	0	0/4 (0%)
Q1 2025	MMUD	2	0	0/2 (0%)
Q1 2025	Haploidentical	1	1	1/1 (100%)
Q2 2025	MUD	1	0	0/1 (0%)
Q2 2025	Sibling HLA-identical	2	1	1/2 (50%)
Q2 2025	Haploidentical	1	0	0/1 (0%)
Q3 2025	Haploidentical	3	2	2/3 (66.7%)
Q3 2025	MMUD	3	0	0/3 (0%)
Q3 2025	MUD	2	1	1/2 (50%)
Q4 2025	Haploidentical	3	NA	NA/3 (NA%)
Q4 2025	MMUD	2	NA	NA/2 (NA%)
Q4 2025	MUD	2	NA	NA/2 (NA%)

Chronic GVHD (Total/Any) by Quarter, Donor Type, and CR Status

Table 8: Chronic GVHD (Any) by Quarter, Donor Type, and Complete Remission Status

Quarter	CR Status	Donor Type	N	Events	Chronic GVHD (Any) Rate (n/N %)
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)
Q1 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q1 2025	Complete Remission	Haploidentical	1	1	1/1 (100%)
Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	1	1/2 (50%)
Q3 2025	Complete Remission	Haploidentical	3	2	2/3 (66.7%)
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)

Q3 2025	Complete Remission	MUD	2	1	1/2 (50%)
Q4 2025	Complete Remission	Haploidentical	3	NA	NA/3 (NA%)
Q4 2025	Complete Remission	MMUD	1	NA	NA/1 (NA%)
Q4 2025	Complete Remission	MUD	1	NA	NA/1 (NA%)
Q4 2025	Not in Complete Remission	MUD	1	NA	NA/1 (NA%)
Q4 2025	Not in Complete Remission	MMUD	1	NA	NA/1 (NA%)

Chronic GVHD (Mild) Analysis

Chronic GVHD (Mild) by Quarter - Overall

Table 9: Chronic GVHD (Mild) by Quarter

Quarter	N	Events	Chronic GVHD (Mild) Rate (n/N %)
Q1 2025	7	1	1/7 (14.3%)
Q2 2025	4	0	0/4 (0%)
Q3 2025	8	0	0/8 (0%)
Q4 2025	7	0	0/7 (0%)

Chronic GVHD (Mild) by Quarter and Complete Remission Status

Table 10: Chronic GVHD (Mild) by Quarter and Complete Remission Status

Quarter	Disease Status	N	Events	Chronic GVHD (Mild) Rate (n/N %)
Q1 2025	Complete Remission	5	1	1/5 (20%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)
Q2 2025	Not in Complete Remission	2	0	0/2 (0%)
Q3 2025	Complete Remission	8	0	0/8 (0%)
Q4 2025	Complete Remission	5	0	0/5 (0%)
Q4 2025	Not in Complete Remission	2	0	0/2 (0%)

Chronic GVHD (Mild) by Quarter and Donor Type

Table 11: Chronic GVHD (Mild) by Quarter and Donor Type

Quarter	Donor Type	N	Events	Chronic GVHD (Mild) Rate (n/N %)
Q1 2025	MUD	4	0	0/4 (0%)
Q1 2025	MMUD	2	0	0/2 (0%)
Q1 2025	Haploidentical	1	1	1/1 (100%)
Q2 2025	MUD	1	0	0/1 (0%)
Q2 2025	Sibling HLA-identical	2	0	0/2 (0%)
Q2 2025	Haploidentical	1	0	0/1 (0%)
Q3 2025	Haploidentical	3	0	0/3 (0%)
Q3 2025	MMUD	3	0	0/3 (0%)
Q3 2025	MUD	2	0	0/2 (0%)
Q4 2025	Haploidentical	3	0	0/3 (0%)
Q4 2025	MMUD	2	0	0/2 (0%)
Q4 2025	MUD	2	0	0/2 (0%)

Chronic GVHD (Mild) by Quarter, Donor Type, and CR Status

Table 12: Chronic GVHD (Mild) by Quarter, Donor Type, and Complete Remission Status

Quarter	CR Status	Donor Type	N	Events	Chronic GVHD (Mild) Rate (n/N %)
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)
Q1 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q1 2025	Complete Remission	Haploidentical	1	1	1/1 (100%)
Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	0	0/2 (0%)
Q3 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)
Q3 2025	Complete Remission	MUD	2	0	0/2 (0%)
Q4 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)
Q4 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q4 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)

Chronic GVHD (Moderate-Severe) Analysis

Chronic GVHD (Moderate-Severe) by Quarter - Overall

Table 13: Chronic GVHD (Moderate-Severe) by Quarter

Quarter	N	Events	Chronic GVHD (Mod-Severe) Rate (n/N %)
Q1 2025	7	0	0/7 (0%)
Q2 2025	4	1	1/4 (25%)
Q3 2025	8	3	3/8 (37.5%)
Q4 2025	7	0	0/7 (0%)

Chronic GVHD (Moderate-Severe) by Quarter and Complete Remission Status

Table 14: Chronic GVHD (Moderate-Severe) by Quarter and Complete Remission Status

Quarter	Disease Status	N	Events	Chronic GVHD (Mod-Severe) Rate (n/N %)
Q1 2025	Complete Remission	5	0	0/5 (0%)
Q1 2025	Not in Complete Remission	2	0	0/2 (0%)
Q2 2025	Complete Remission	2	0	0/2 (0%)
Q2 2025	Not in Complete Remission	2	1	1/2 (50%)
Q3 2025	Complete Remission	8	3	3/8 (37.5%)
Q4 2025	Complete Remission	5	0	0/5 (0%)
Q4 2025	Not in Complete Remission	2	0	0/2 (0%)

Chronic GVHD (Moderate-Severe) by Quarter and Donor Type

Table 15: Chronic GVHD (Moderate-Severe) by Quarter and Donor Type

Quarter	Donor Type	N	Events	Chronic GVHD (Mod-Severe) Rate (n/N %)
Q1 2025	MUD	4	0	0/4 (0%)
Q1 2025	MMUD	2	0	0/2 (0%)
Q1 2025	Haploidentical	1	0	0/1 (0%)
Q2 2025	MUD	1	0	0/1 (0%)
Q2 2025	Sibling HLA-identical	2	1	1/2 (50%)
Q2 2025	Haploidentical	1	0	0/1 (0%)
Q3 2025	Haploidentical	3	2	2/3 (66.7%)

Q3 2025	MMUD	3	0	0/3 (0%)
Q3 2025	MUD	2	1	1/2 (50%)
Q4 2025	Haploidentical	3	0	0/3 (0%)
Q4 2025	MMUD	2	0	0/2 (0%)
Q4 2025	MUD	2	0	0/2 (0%)

Chronic GVHD (Moderate-Severe) by Quarter, Donor Type, and CR Status

Table 16: Chronic GVHD (Moderate-Severe) by Quarter, Donor Type, and Complete Remission Status

Quarter	CR Status	Donor Type	N	Events	Chronic GVHD (Mod-Severe)
Q1 2025	Complete Remission	MUD	3	0	0/3 (0%)
Q1 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q1 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q1 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q2 2025	Complete Remission	Haploidentical	1	0	0/1 (0%)
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	1	1/2 (50%)
Q3 2025	Complete Remission	Haploidentical	3	2	2/3 (66.7%)
Q3 2025	Complete Remission	MMUD	3	0	0/3 (0%)
Q3 2025	Complete Remission	MUD	2	1	1/2 (50%)
Q4 2025	Complete Remission	Haploidentical	3	0	0/3 (0%)
Q4 2025	Complete Remission	MMUD	1	0	0/1 (0%)
Q4 2025	Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MUD	1	0	0/1 (0%)
Q4 2025	Not in Complete Remission	MMUD	1	0	0/1 (0%)

Summary Tables

All GVHD Endpoints Summary by Quarter

Table 17: All GVHD Endpoints Summary by Quarter

Quarter	N	Acute GVHD II-IV		Chronic GVHD (Any)		Chronic GVHD (Mild)		Chronic GVHD (Severe)	
		Events	Rate (n/N %)	Events	Rate (n/N %)	Events	Rate (n/N %)	Events	Rate (n/N %)
Q1 2025	7	2	2/7 (28.6%)	1	1/7 (14.3%)	1	1/7 (14.3%)	0	0/7 (0%)
Q2 2025	4	0	0/4 (0%)	1	1/4 (25%)	0	0/4 (0%)	1	1/4 (25%)
Q3 2025	8	4	4/8 (50%)	3	3/8 (37.5%)	0	0/8 (0%)	3	3/8 (37.5%)
Q4 2025	7	1	1/7 (14.3%)	NA	NA/7 (NA%)	0	0/7 (0%)	0	0/7 (0%)

Overall GVHD Event Summary

Table 18: Summary of GVHD Endpoints - 2025 Cohort (N=26)

GVHD Endpoint	Total Events	Overall Rate (n/N %)
Acute GVHD Grade II-IV	7	7/26 (26.9%)
Chronic GVHD (Any)	NA	NA/26 (NA%)
Chronic GVHD (Mild)	1	1/26 (3.8%)
Chronic GVHD (Moderate-Severe)	4	4/26 (15.4%)

Key Observations

Acute GVHD Grade II-IV:

- Total events: 7/26 (26.9%)
- Clinically significant acute GVHD requiring treatment

Chronic GVHD (Any):

- Total events: NA/26 (NA%)
- May be underestimated due to limited follow-up

Chronic GVHD (Mild):

- Total events: 1/26 (3.8%)

- Limited/mild disease

****Chronic GVHD (Moderate-Severe):****

- Total events: 4/26 (15.4%)
- Clinically significant chronic GVHD

! Important Limitations

Limited Follow-up for Chronic GVHD: - Chronic GVHD typically develops 3-12+ months post-transplant - Q3 and Q4 2025 patients have insufficient follow-up - True chronic GVHD rates likely higher with longer follow-up

Median follow-up: 169 days

Interpretation: - Acute GVHD rates are more reliable (occurs early post-transplant) - Chronic GVHD rates should be interpreted with caution - Longer follow-up needed for definitive chronic GVHD assessment

Report generated on January 21, 2026

Analysis includes only patients transplanted in calendar year 2025, organized by quarter (trimester)

GVHD endpoints: Acute GVHD Grade II-IV, Chronic GVHD (Total, Mild, Moderate-Severe)